Anticancer agent 91
Anticancer agent 91 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. Anticancer agent 91 has high inhibition against the two cell line from CNS cancer (SF-539 and SNB-75).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2977251-00-4
- Formule: C33H32N2O10S3
- Masse moléculaire:712.81
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
Description
In Vitro
Anticancer agent 91 (compound 6a) (0.01 mM; 24 h) has low cytotoxicity, shows high inhibition against SF-539, SNB-75 and HCT-116[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines
-
Concentration:0-200 μg/mL
-
Incubation Time:24 hours
-
Result:Showed nontoxic under the doses of 90 μg/mL against FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cells, respectively.
-
Cell Line:SF-539, SNB-75
-
Concentration:0.01 mM
-
Incubation Time:24 hours
-
Result:Inhibited SF-539, SNB-75 and HCT-116 cell viability by 28.19%, 25.40%, respectively.
Chemical Information
-
CAS No. 2977251-00-4
-
Masse moléculaire 712.81
-
Formule C33H32N2O10S3
-
SMILES
O=C(C1=C(N)C(C2=NC3=CC=CC=C3S2)=C(S[C@H]4[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@](OC(C)=O)([H])[C@@H](COC(C)=O)O4)S1)C5=CC=C(C)C=C5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 91 Related Classifications
HY-151592 Related Classifications
Powered by Bioz